Does Rallies show Form 4 insider transactions for BSX?

Yes. Rallies tracks BSX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BSX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.

BSX (Boston Scientific) Stock Analysis - Insider Trades

Boston Scientific (BSX) is a publicly traded Healthcare sector company. As of May 20, 2026, BSX trades at $56.63 with a market cap of $83.12B and a P/E ratio of 23.46. BSX moved -0.42% today. Year to date, BSX is -40.65%; over the trailing twelve months it is -46.81%. Its 52-week range spans $52.52 to $109.50. Analyst consensus is strong buy with an average price target of $89.12. Rallies surfaces BSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BSX stock inside the company?

Recent BSX insider activity includes Mahoney Michael F sold 1.20K, Mahoney Michael F sold 159.70K, Butcher Arthur C sold 17.31K, Zane Ellen M sold 12.89K, and Fitzgerald Joseph Michael sold 3.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BSX Key Metrics

Key financial metrics for BSX
Metric	Value
Price	$56.63
Market Cap	$83.12B
P/E Ratio	23.46
EPS	$2.41
Dividend Yield	0.00%
52-Week High	$109.50
52-Week Low	$52.52
Volume	12.02M
Avg Volume	0
Revenue (TTM)	$20.61B
Net Income	$3.56B
Gross Margin	69.17%

Recent BSX Insider Trades

Mahoney Michael F sold 1.20K (~$112.87K) on Feb 2, 2026.
Mahoney Michael F sold 159.70K (~$14.93M) on Feb 2, 2026.
Butcher Arthur C sold 17.31K (~$1.76M) on Dec 1, 2025.
Zane Ellen M sold 12.89K (~$1.27M) on Nov 6, 2025.
Fitzgerald Joseph Michael sold 3.60K (~$362.69K) on Nov 3, 2025.

Latest BSX News

Boston Scientific Coronary IVL Catheter Hits 93.3% Safety, 93.7% Effectiveness — May 19, 2026
Boston Scientific Invests $1.5B for 34% MiRus Stake with $3B TAVR Option — May 18, 2026
Boston Scientific Launches $2B Accelerated Buyback, Secures 30.4M Shares — May 18, 2026
Boston Scientific’s $1.5B Investment Secures 34% Stake and $3B Option in TAVR Valve — May 18, 2026
Penumbra’s Q1 Revenue Jumps 15.6% to $374.8 Million with $9.4M Acquisition Expense — May 6, 2026

BSX Analyst Consensus

27 analysts cover BSX: 0 strong buy, 26 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.12.

Common questions about BSX

Who is trading BSX stock inside the company?: Recent BSX insider activity includes Mahoney Michael F sold 1.20K, Mahoney Michael F sold 159.70K, Butcher Arthur C sold 17.31K, Zane Ellen M sold 12.89K, and Fitzgerald Joseph Michael sold 3.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BSX?: Yes. Rallies tracks BSX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BSX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BSX. It does not provide personalized investment advice.